GTC Biotherapeutics (fka GTCB)

[goatfondler]

My last post.... Dew would rather focus on my tongue in cheek name rather than the substance of what I write.

My thoughts on GTCB is that it's an undervalued biotech that, for some reason, has a bad relationship with the investing community (Wall St, institutions, etc). For what it's accomplished so far, you have to scratch your head and wonder why it's stuck where it is with very little attention by brokerage firms.

Biotechs in general are "risky" investments especially when they are in the developmental stages. GTCB still has one foot in the developmental door but has progressed with at least one EU approved drug (unfortunately not yet approved in the US). So to answer your question, GTCB is attractively priced right now before the launch. But, my gut feeling is that GTCB management has failed to make a case to the investment community that they have a business that is capable of making money. That's why the stock is where it is at. Just look at what Pharming's stock price and ask why it's selling at a much higher price than GTCB.